Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Legal Names
Legal name
Similar Companies1000
Aptose Biosciences
Aptose Biosciences is a biopharmaceutical company that develops novel anticancer therapies with high safety profiles.
Sector
Subsector
Keywords
Location
total rounds
total raised
Flame Biosciences
Flame Biosciences develops value-added medicines in the emerging area of inflammasome science.
Sector
Subsector
Keywords
Location
total rounds
total raised
Anchiano Therapeutics
Anchiano is a clinical-stage biopharmaceutical company that develops novel cancer therapies.
Sector
Subsector
Keywords
Location
total rounds
total raised
Apollomics
Apollomics develops oncology therapies to eradicate cancer by harnessing the immune system and targeting molecular pathways.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
Financials
Funding Rounds7
Number of Funding Rounds
Money Raised
Their latest funding was raised on 27.08.2024. Their latest investor Hercules Capital. Their latest round Post-IPO Debt
Hercules Capital
Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, innovative venture capital-backed companies.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that develops and commercializes innovative medicines.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that develops and commercializes innovative medicines.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Co-Investors
Investors11
Number of lead investors
Number of investors
Hercules Capital
Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, innovative venture capital-backed companies.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Celgene
Celgene develops and sells innovative therapies for cancer and immune-inflammatory diseases.
Sector
Subsector
Location
count Of Investments
count Of Exists
Taiho Ventures
Taiho Ventures is a venture capital firm that invests in early-stage pharmaceutical companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders2
Juan Jaen
Juan has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded Arcus Biosciences together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1.25 billion. Previously, he was Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Juan led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. At ChemoCentryx, Juan led the discovery efforts for the multi-year collaboration with GSK, which generated over $100M in non-dilutive milestones and fees. From 1996 to 2006, Juan held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen Inc. (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry. From 1983 to 1996, Juan held various scientific leadership positions at Parke-Davis/Warner-Lambert. Juan holds a Visiting Scholar appointment (ChEM-H) at Stanford University and is a member of the Scientific Advisory Board at Cleave Biosciences. Juan obtained a B.S. degree in Chemistry from Universidad Complutense in Madrid (Spain) and a Ph.D. degree in Organic Chemistry from the University of Michigan. He has co-authored over 100 scientific papers and is an inventor on 50 issued U.S. patents. Juan has been responsible for the advancement of over 20 novel molecules into clinical development for diseases including cancer, Alzheimer’s, Crohn’s, RA, diabetes and diabetic nephropathy, psoriasis, asthma, and vasculitis, among others.
current job
count Of Investments
Juan Jaen
Employee Profiles36
Activity
Recent News46
The graph reveals the ratio (%) of positive news articles in a chosen time range